Management of low-risk metastatic gestational trophoblastic tumors.
The clinical course of 48 patients with low-risk metastatic gestational trophoblastic tumors (GTTs) treated with primary single-agent chemotherapy was reviewed. All patients achieved sustained remission, although 25 (51%) required a second single-agent regimen, and 7 (14%) needed combination chemotherapy to achieve it. An average of 3.4 courses of chemotherapy were necessary to achieve remission, and 6 patients (12%) underwent resection of resistant tumor foci. Primary single-agent chemotherapy is a reasonable treatment option in patients with low-risk metastatic GTT.
DuBeshter
B
B
Department of Obstetrics and Gynecology, University of Rochester School of Medicine, Strong Memorial Hospital, NY.
Berkowitz
R S
RS
Goldstein
D P
DP
Bernstein
M R
MR
D001219:Aspartate Aminotransferases / Q000032:analysis / Q000187:drug effects; D003609:Dactinomycin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006098:Granulocytes / Q000737:chemistry / Q000187:drug effects; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D010976:Platelet Count / Q000187:drug effects; D011247:Pregnancy; D011379:Prognosis; D012074:Remission Induction; D014328:Trophoblastic Neoplasms / Q000097:blood / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy*
D003609:Dactinomycin; D001219:Aspartate Aminotransferases; D002955:Leucovorin; D008727:Methotrexate